Selective estrogen receptor modulators (SERMs) and retinoids in breast cancer chemoprevention

Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

1998 • 5,487 citations

Tamoxifen for early breast cancer: an overview of the randomised trials

1998 • 4,082 citations

Projecting Individualized Probabilities of Developing Breast Cancer for White Females Who Are Being Examined Annually

1989 • 3,239 citations

Circulating concentrations of insulin-like growth factor I and risk of breast cancer

1998 • 1,850 citations

Differential Ligand Activation of Estrogen Receptors ERα and ERβ at AP1 Sites

1997 • 1,808 citations

Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal Women

1997 • 1,641 citations

Effects of Tamoxifen on Bone Mineral Density in Postmenopausal Women with Breast Cancer

1992 • 1,139 citations

Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids).

1976 • 993 citations

Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial

1998 • 890 citations

Mammographic Features and Breast Cancer Risk: Effects With Time, Age, and Menopause Status

1995 • 860 citations

Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women

1998 • 774 citations

Tamoxifen and Breast Cancer Incidence Among Women With Inherited Mutations in BRCA1 and BRCA2

2001 • 750 citations

Basic guide to the mechanisms of antiestrogen action.

1998 • 688 citations

Weighing the Risks and Benefits of Tamoxifen Treatment for Preventing Breast Cancer

1999 • 676 citations

Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women.

1996 • 640 citations

Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats.

1994 • 614 citations

Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study

2000 • 536 citations

Retinoids in cancer therapy.

1992 • 505 citations

Retinoids in cancer chemoprevention

1996 • 432 citations

Randomized Trial of Fenretinide to Prevent Second Breast Malignancy in Women With Early Breast Cancer

1999 • 416 citations

Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice.

1985 • 396 citations

Potential Role of Tamoxifen in Prevention of Breast Cancer

1991 • 387 citations

Effects of Tamoxifen on Cardiovascular Risk Factors in Postmenopausal Women

1991 • 380 citations

Retinoids as preventive and therapeutic anticancer agents (Part I).

1987 • 361 citations

Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice.

1989 • 334 citations

Effects of Tamoxifen on Cardiovascular Risk Factors in Postmenopausal Women After 5 Years of Treatment

1994 • 279 citations

The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat

1993 • 235 citations

Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand.

1996 • 202 citations

4-Hydroxyphenyl Retinamide Is a Highly Selective Activator of Retinoid Receptors

1996 • 183 citations

Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women

1998 • 182 citations

Growth hormone treatment induces mammary gland hyperplasia in aging primates

1997 • 175 citations

Chemoprevention of Mammary Carcinogenesis in the Rat: Combined Use of Raloxifene and 9-cis-Retinoic Acid

1996 • 172 citations

The Royal Marsden Hospital pilot tamoxifen chemoprevention trial

1994 • 156 citations

Non-linearity of neoplastic conversion induced in rat liver by low exposures to diethylnitrosamine

1993 • 148 citations

Changes in Mammographic Densities Induced by a Hormonal Contraceptive Designed to Reduce Breast Cancer Risk

1994 • 144 citations

Synthetic retinoid fenretinide is effective against a human ovarian carcinoma xenograft and potentiates cisplatin activity.

1993 • 134 citations

N-(4-hydroxyphenyl)retinamide (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma

1995 • 129 citations

Tamoxifen induces hepatocellular carcinoma in rat liver: A 1-year study with two antiestrogens

1993 • 127 citations

Clinical potential of new antiestrogens.

1997 • 127 citations

Tolerability of the synthetic retinoid fenretinide® (HPR)

1989 • 126 citations

Retinoic Acid Receptor β Expression and Growth Inhibition of Gynecologic Cancer Cells by the Synthetic Retinoid N-(4-Hydroxyphenyl) Retinamide

1998 • 115 citations

Effect of tamoxifen on mammographic density.

2000 • 106 citations

Interference of the IGF system as a strategy to inhibit breast cancer growth

1992 • 100 citations

Regulation of breast cancer growth by insulin-like growth factors

1990 • 100 citations

Reproductive Endocrine and Endometrial Effects of Raloxifene Hydrochloride, a Selective Estrogen Receptor Modulator, in Women with Regular Menstrual Cycles1

1998 • 94 citations

Prevention--therapy--basic science and the resolution of the cancer problem.

1993 • 93 citations

Mammographic Densities and Risk of Breast Cancer Among Subjects With a Family History of This Disease

1999 • 91 citations

Antiestrogenic properties of keoxifene,trans-4-hydroxytamoxifen, and ICI 164384, a new steroidal antiestrogen, in ZR-75-1 human breast cancer cells

1989 • 87 citations

Comparison of N-(4-hydroxyphenyl)retinamide and all-trans-retinoic acid in the regulation of retinoid receptor-mediated gene expression in human breast cancer cell lines.

1996 • 85 citations

Interaction of Retinoids and Tamoxifen on the Inhibition of Human Mammary Carcinoma Cell Proliferation

1987 • 84 citations

Chemoprevention of cancer

1993 • 81 citations

Pilot Trial of the Safety, Tolerability, and Retinoid Levels of N-(4-hydroxyphenyl) Retinamide in Combination With Tamoxifen in Patients at High Risk for Developing Invasive Breast Cancer

2000 • 72 citations

Effect of the Synthetic Retinoid Fenretinide on Dark Adaptation and the Ocular Surface

1994 • 64 citations

Chemoprevention of MNU-induced mammary tumors in the mature rat by 4-HPR and tamoxifen.

1992 • 61 citations

The effects of retinoids on proliferative capacities and macromolecular synthesis in human breast cancer MCF-7 cells

1980 • 52 citations

Role of retinoic acid receptor overexpression in sensitivity to fenretinide and tumorigenicity of human ovarian carcinoma cells

1999 • 50 citations

Effect of fenretinide on plasma IGF-I and IGFBP-3 in early breast cancer patients

1998 • 47 citations

Phase I Clinical Trial of Alitretinoin and Tamoxifen in Breast Cancer Patients: Toxicity, Pharmacokinetic, and Biomarker Evaluations

2001 • 47 citations

Effect of N-(4-hydroxyphenyl)retinamide on apoptosis in human breast cancer cells

1996 • 44 citations

Reproductive Endocrine and Endometrial Effects of Raloxifene Hydrochloride, a Selective Estrogen Receptor Modulator, in Women with Regular Menstrual Cycles

1998 • 42 citations

Regulation of Estrogen Receptor α Function in Breast Cancer

1997 • 37 citations

Tamoxifen and Secondary Tumours

1997 • 36 citations

Inhibition of Human Mammary Carcinoma Cell Proliferation by Retinoids and Intracellular cAMP-Elevating Compounds<xref ref-type="fn" rid="FN2">2</xref>

1987 • 34 citations

The incidence of hepatocellular carcinoma in US white women with breast cancer after the introduction of tamoxifen in 1977

1994 • 28 citations

Chemoprevention of breast cancer: The Italian experience

2000 • 26 citations

Clinical development of estrogen modulators for breast cancer chemoprevention in premenopausal vs. postmenopausal women

2000 • 9 citations